Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions

JACC: Heart Failure

Volumn 5, Issue 11, 2017, Pages 763-771

  Hsu, Jeffrey J ^a   Ziaeian, Boback ^a,b   Fonarow, Gregg C ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

epidemiology; heart failure with borderline ejection fraction; heart failure with mid range ejection fraction; heart failure with preserved ejection fraction; HFbEF; HFmrEF; HFpEF; outcomes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENKEPHALINASE INHIBITOR; IRBESARTAN; SACUBITRIL PLUS VALSARTAN; VALSARTAN;

CARDIOVASCULAR RISK; CLINICAL FEATURE; COMORBIDITY; CONGESTIVE HEART FAILURE; EPIDEMIOLOGICAL DATA; HEART FAILURE WITH MID RANGE EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MORBIDITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT INDICATION; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; PHYSIOLOGY;

DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; HEART FAILURE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 85030857433     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2017.06.013     Document Type: Review

References (37)

1. Wang, T.J., Evans, J.C., Benjamin, E.J., Levy, D., LeRoy, E.C., Vasan, R.S., Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 108 (2003), 977–982.
2. Fonarow, G.C., Stough, W.G., Abraham, W.T., et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 50 (2007), 768–777.
3. Butler, J., Fonarow, G.C., Zile, M.R., et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. J Am Coll Cardiol HF 2 (2014), 97–112.
4. Sweitzer, N.K., Lopatin, M., Yancy, C.W., Mills, R.M., Stevenson, L.W., Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (<40%) fractions. Am J Cardiol 101 (2008), 1151–1156.
5. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
6. Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 (2016), 2129–2200.
7. Lam, C.S., Solomon, S.D., Fussing over the middle child: heart failure with mid-range ejection fraction. Circulation 135 (2017), 1279–1280.
8. Cheng, R.K., Cox, M., Neely, M.L., et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J 168 (2014), 721–730.
9. Benjamin, E.J., Blaha, M.J., Chiuve, S.E., et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation 135 (2017), e146–e603.
10. Kapoor, J.R., Kapoor, R., Ju, C., et al. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. J Am Coll Cardiol HF 4 (2016), 464–472.
11. Tsuji, K., Sakata, Y., Nochioka, K., et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction—a report from the CHART-2 Study. Eur J Heart Fail, 2017 Mar 31 [E-pub ahead of print].
12. Coles, A.H., Tisminetzky, M., Yarzebski, J., et al. Magnitude of and prognostic factors associated with 1-year mortality after hospital discharge for acute decompensated heart failure based on ejection fraction findings. J Am Heart Assoc, 4, 2015, e002303.
13. Steinberg, B.A., Zhao, X., Heidenreich, P.A., et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 126 (2012), 65–75.
14. Rickenbacher, P., Kaufmann, B.A., Maeder, M.T., et al. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified Versus Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF). Eur J Heart Fail, 2017 Mar 15 [E-pub ahead of print].
15. Lee, D.S., Gona, P., Vasan, R.S., et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 119 (2009), 3070–3077.
16. Borlaug, B.A., Redfield, M.M., Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 123 (2011), 2006–2013 discussion 2014.
17. Bhatia, R.S., Tu, J.V., Lee, D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 (2006), 260–269.
18. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 33 (2012), 1750–1757.
19. Solomon, S.D., Anavekar, N., Skali, H., et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 112 (2005), 3738–3744.
20. Pocock, S.J., Ariti, C.A., McMurray, J.J., et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 34 (2013), 1404–1413.
21. Löfman, I., Szummer, K., Dahlström, U., Jernberg, T., Lund, L.H., Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail, 2017 Mar 29 [E-pub ahead of print].
22. Coles, A.H., Fisher, K., Darling, C., et al. Long-term survival for patients with acute decompensated heart failure according to ejection fraction findings. Am J Cardiol 114 (2014), 862–868.
23. Pitt, B., Pfeffer, M.A., Assmann, S.F., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 (2014), 1383–1392.
24. Solomon, S.D., Claggett, B., Lewis, E.F., et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37 (2016), 455–462.
25. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol, 2017 Apr 21 [E-pub ahead of print].
26. Yusuf, S., Pfeffer, M.A., Swedberg, K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet Lond Engl 362 (2003), 777–781.
27. Massie, B.M., Carson, P.E., McMurray, J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 (2008), 2456–2467.
28. Hernandez, A.F., Hammill, B.G., O'Connor, C.M., Schulman, K.A., Curtis, L.H., Fonarow, G.C., Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 53 (2009), 184–192.
29. Felker, G.M., Ahmad, T., Anstrom, K.J., et al. Rationale and design of the GUIDE-IT study: guiding evidence based therapy using biomarker intensified treatment in heart failure. J Am Coll Cardiol HF 2 (2014), 457–465.
30. Dunlay, S.M., Roger, V.L., Weston, S.A., Jiang, R., Redfield, M.M., Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail 5 (2012), 720–726.
31. Ather, S., Chan, W., Bozkurt, B., et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 59 (2012), 998–1005.
32. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
33. Martens, P., Mathieu, C., Verbrugge, F.H., Promise of SGLT2 inhibitors in heart failure: diabetes and beyond. Curr Treat Options Cardiovasc Med, 19, 2017, 23.
34. Klem, I., Weinsaft, J.W., Bahnson, T.D., et al. Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. J Am Coll Cardiol 60 (2012), 408–420.
35. Halliday, B., Gulati, A., Ali, A., et al. Association between mid-wall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation 135 (2017), 2106–2115.
36. Adamson, P.B., Abraham, W.T., Bourge, R.C., et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 7 (2014), 935–944.
37. Chow, S.L., Maisel, A.S., Anand, I., et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation 135 (2017), e1054–e1091.